Belluscura Logo

Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Belluscura PLC
(“Belluscura” or the “Company” or “Group”)

Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS)

X-PLO2R™ portable oxygen concentrator now covered by two Medicare reimbursement codes

LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Medicare Administrative Contractor Palmetto GBA MolDx (“Palmetto”) has issued a final local coverage determination for the X-PLO2R™ portable oxygen concentrator (“X-PLO2R”). Weighing only 3.25 lbs (1.5kg), the X-PLO2R is the world’s first portable modular oxygen concentrator.

Medicare reimbursement covers approximately 50% of the oxygen concentrator market in the US. The Board believes the approval of the two reimbursement codes will have a positive impact on the Company and expects to update shareholders on the full-year outcome for FY21 in early January 2022.

Robert Rauker, CEO of Belluscura plc, commented: “Receiving the two Medicare reimbursement codes should further expand access and the use and distribution of the X-PLO2R throughout the US. We believe many Medicare patients will ask their health care providers and durable medical equipment providers to issue them with the lightweight X-PLO2R.”

For further information please contact:

Belluscura plc www.belluscura.com

Robert Rauker, Chief Executive Officer via Walbrook PR
Anthony Dyer, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD) Tel: +44 (0)20 3368 3550
Neil Baldwin

Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers

Walbrook PR Ltd (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com

Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers, and insurance organizations.

Belluscura Logo

Exercise of Warrants and Total Voting Rights

Belluscura PLC
(“Belluscura” or “Company”)

Exercise of Warrants and Total Voting Rights

LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from a warrant holder to exercise warrants over 179,537 shares in the share capital of Belluscura (“the Warrant Shares”) at exercise prices of 13 pence (139,537 shares) and 15 pence (40,000 shares). The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £24,139.81.

The Warrant Shares were allotted on 26 November 2021. Application has been made for the Warrant Shares to be admitted to trading on AIM (“Admission”), and Admission is expected to be on or around 2 December 2021. These shares will rank pari passu with the ordinary shares of the Company in the issue.

Total voting rights

The Company’s total issued capital, after the issue of the Warrant Shares, will be 113,486,938 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

Belluscura plc www.belluscura.com

Robert Rauker, Chief Executive Officer via Walbrook PR
Anthony Dyer, Chief Financial Officer

SPARK Advisory Partners Ltd (NOMAD) Tel: +44 (0)20 3368 3550
Neil Baldwin

Dowgate Capital Ltd (Broker & Bookrunner) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers

Walbrook PR Ltd (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com

Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258